Investigation of DHA Intake in Pregnant and Lactating Women in China
調査の概要
状態
条件
詳細な説明
This is a multi-center, cross-sectional, non-interventional, observational study in 816 pregnant (gestation week 17±2 group and gestation week 39±2 group 408 cases in each group) and 408 lactating women (post-natal lactation day 42±7 group) from a total of 4 sites in 3 typical areas (1 coastal regions, 2 inland regions and 1 lake regions) in China to study the correlation between DHA intake and DHA concentrations in blood and breast milk. Investigators are mainly physicians majoring in gynaecology and obstetrics, etc. During visits, the study physician will record the patient's social demographic data, disease and relevant medication history, review her medical records, assess DHA intake by the DHA Screener, and determine DHA concentrations in erythrocyte membrane, plasma and breast milk, so as to validate the feasibility of DHA Screener as DHA intake assessment tool for determining DHA concentrations in the body.
Subjects meeting inclusion criteria and non of the exclusion criteria will be informed of relevant information of the study. Subjects should be voluntarily consent to participate in the study and sign the informed consent form.
Screening of the study is scheduled for as long as 5 months. In this study, additional examinations or other interventions are not required.
研究の種類
入学 (実際)
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
PREGNANT WOMEN:
- Healthy women presenting at their week 17±2 and week 39±2 obstetric examination;
- 18-40 years of age;
- Monocyesis;
- Having signed the informed consent form voluntarity before participating in the study.
LACTATING WOMEN:
- Healthy women presenting at their day 42±7 post-natal visit;
- 18-40 years of age;
- Monocyesis;
- Having signed the informed consent form voluntarily before participating in the study
Exclusion Criteria:
- Administration of DHA supplements (milk powder for pregnant women, DHA soft capsule, Zmarto, NURIZ, Naturies, HeadDHA, Beibeicong, Nutrimed etc);
- Still experiencing severe vomiting after 16 weeks of pregnancy;
- Women who have heart, liver, kidney, (ALT and AST≥ 1.5 times of normal upper limit, Cr>normal upper limit) or severe lung disease or laboratory abnormality (i.e.lipid metabolism disorder) that may interfere with the interpretation of study results, as indicated in previous examinations;
- Pregnant woman currently participating in other clinical trials or who have participated in another clinical trial in the last 30 days;
- Women who in the judgement of the investigator cannot be expected to comply with the protocol or study procedures.
研究計画
研究はどのように設計されていますか？
デザインの詳細
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
To evaluate the feasibility in using DHA Screener for determination of internal DHA concentration
時間枠：5 months
|
Correlation between DHA Screener and DHA concentration in plasma; Correlation between DHA Screener and DHA concentration in erythrocyte membrane; Correlation between DHA Screener and DHA concentration in breast milk.
|
5 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
To compare the correlation between DHA Screener and RBC DHA among different subgroups. To compare DHA intake assessed by DHA Screener against Chinese recommendations of DHA intake.
時間枠：5 months
|
|
5 months
|
|
To compare DHA intake assessed by DHA Screener against Chinese recommendations of DHA intake.
時間枠：5 months
|
To compare DHA intake assessed by DHA Screener against Chinese recommendations of DHA intake.
|
5 months
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
To assess the correlation between DHA intake and DHA concentrations in the blood and breast milk of lactating women
時間枠：5 months
|
To assess the correlation between DHA intake and DHA concentrations in the blood and breast milk of lactating women
|
5 months
|
協力者と研究者
スポンサー
捜査官
- スタディチェア：Jianmeng Liu, Doctor、Peking University
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- 14.10.CN.INF
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。